Intra-wound Vancomycin Powder for Prevention of Surgical Site Infection Following Spinal Surgery - Trial NCT05959603
Access comprehensive clinical trial information for NCT05959603 through Pure Global AI's free database. This Phase 3 trial is sponsored by Rabin Medical Center and is currently Recruiting. The study focuses on Infection. Target enrollment is 363 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Rabin Medical Center
Timeline & Enrollment
Phase 3
May 31, 2020
Dec 01, 2024
Primary Outcome
Incidence of deep spinal infections
Summary
Cefazolin is given routinely pre and intraoperatively for patients undergoing spinal surgery
 to reduce the rate of infection. Intra-wound admission of Vancomycin powder has been
 suggested to reduce wound infection rates. Therefore, this study aims to compare the rate of
 wound-related complications between patients receiving standard treatment compared to
 patients receiving an addition of topical Vancomycin and to identify the optimal Vancomycin
 dosage. All groups will receive the recommended regimen of routine IV antibiotic prophylaxis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05959603
Non-Device Trial